Eden Biodesign and ImmBio to develop next generation flu vaccine
Eden Biodesign, of Liverpool in the UK, has been selected by Cambridge-based biotech company ImmBio to provide a range of development and manufacturing services for its leading influenza vaccine programme.
Eden Biodesign, of Liverpool in the UK, has been selected by Cambridge-based biotech company ImmBio to provide a range of development and manufacturing services for its leading influenza vaccine programme.
This targets both seasonal and pandemic flu, where manufacturing speed and flexibility are critical to meet unmet market needs.
'Working with Eden Biodesign will allow us to rapidly advance the next generation influenza vaccine forward towards a clinical trial application,' said Graham Clarke, ceo of ImmBio.
Eden Biodesign is the operator of the National Biomanufacturing Centre (NBC) facility, part of the £34.25m project developed and owned by the North West Development Agency (NWDA) and funded by the NWDA, the European Regional Development Fund and the Department for Trade and Industry.
'We are very pleased to work with ImmBio on the further development of this promising vaccine and to accelerate its progress from research to the clinic,' added Eden Biodesign ceo Dr Crawford Brown. 'Eden Biodesign has the expertise in product development and manufacturing that is critical to ensure clinical and commercial success of this product.'